secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2026-08-12T11:02:30+00:00
Accession:  0001628280-26-055940
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acumen Q2 2026 net loss $32.7M, cash $110.2M; ALTITUDE-AD topline due late 2026
-------------------------------------------------------------------------------

- Net loss $32.7M vs $41.0M in Q2 2025; loss from operations $32.6M.
- Cash and equivalents $110.2M at June 30, 2026, down from $128.4M at March 31; funds into early 2027.
- R&D expenses $27.8M vs $37.1M prior year on lower ALTITUDE-AD manufacturing and CRO costs.
- Expects topline from Phase 2 ALTITUDE-AD (542 participants, 35/50 mg/kg vs placebo) in late 2026.
- Nominated EBD candidates ACU301 and ACU401; IND submission targeted mid-2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000162828026055940/0001628280-26-055940-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000162828026055940/abos-20260812.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-055940

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer